Sustained production of a soluble IGF-I receptor by gutless adenovirus-transduced host cells protects from tumor growth in the liver

Cancer Gene Therapy

Volumn 20, Issue 4, 2013, Pages 229-236

  Wang, N ^a   Lu, Y ^a   Pinard, M ^a   Pilotte, A ^b   Gilbert, R ^b,c   Massie, B ^b,d   Brodt, P ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cancer; gutless adenoviral vector; liver metastases; soluble IGF IR

Indexed keywords

ADENOVIRUS VECTOR; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENE TARGETING; HOST CELL; IN VITRO STUDY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HEK293 CELLS; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; RECEPTOR, IGF TYPE 1; TRANSDUCTION, GENETIC; TUMOR BURDEN;

ADENOVIRIDAE; MUS;

EID: 84876946791     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.10     Document Type: Article

References (44)

1. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006;13: 668-676.
2. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28: 20-47. (Pubitemid 46220849)
3. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. Embo J. 1986;5: 2503-2512.
4. Garrett TP, McKern NM, Lou M, Frenkel MJ, Bentley JD, Lovrecz GO et al. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 1998;394: 395-399. (Pubitemid 28373839)
5. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16: 143-163.
6. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6: 1-12. (Pubitemid 46206663)
7. Rodon J, DeSantos V, Ferry Jr RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7: 2575-2588.
8. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010;16: 2512-2517.
9. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Research 2012;72: 3-12.
10. Becker CM, Farnebo FA, Iordanescu I, Behonick DJ, Shih MC, Dunning P et al. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther 2002;1: 548-553.
11. Trieu Y, Wen XY, Skinnider BF, Bray MR, Li Z, Claudio JO et al. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res 2004;64: 3271-3275. (Pubitemid 38581432)
12. Tseng JF, Farnebo FA, Kisker O, Becker CM, Kuo CJ, Folkman J et al. Adenovirusmediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery 2002;132: 857-865. (Pubitemid 36307825)
13. Rudge JS, Thurston G, Davis S, Papadopoulos N, Gale N, Wiegand SJ et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol 2005;70: 411-418. (Pubitemid 44124896)
14. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998;9: 1975-1981. (Pubitemid 28463916)
15. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Therap 2001;3: 454-463. (Pubitemid 32998997)
16. Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, Brann T et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 2002;5: 63-73. (Pubitemid 34110482)
17. Vetrini F, Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2010;2: 1886-1917.
18. Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003;107: 2726-2732. (Pubitemid 36667248)
19. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18: 180-183. (Pubitemid 28082470)
20. Samani AA, Chevet E, Fallavollita L, Galipeau J, Brodt P. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 2004;64: 3380-3385. (Pubitemid 38657908)
21. Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J et al. Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol Ther 2009;17: 1241-1249.
22. Brodt P. Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities. Cancer Res 1986;46: 2442-2448. (Pubitemid 16120711)
23. Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 2001;19: 582-585. (Pubitemid 32521193)
24. Gilbert R, Dudley RW, Liu AB, Petrof BJ, Nalbantoglu J, Karpati G. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet 2003;12: 1287-1299. (Pubitemid 36722609)
25. Gilbert R, Liu A, Petrof B, Nalbantoglu J, Karpati G. Improved performance of a fully gutted adenovirus vector containing two full-length dystrophin cDNAs regulated by a strong promoter. Mol Ther 2002;6: 501-509. (Pubitemid 35214872)
26. Meneses-Acosta A, Dormond E, Jacob D, Tom R, Bernier A, Perret S et al. Development of a suspension serum-free helper-dependent adenovirus production system and assessment of co-infection conditions. J Virol Methods 2008;148: 106-114.
27. Gilbert R, Nalbantoglu J, Howell JM, Davies L, Fletcher S, Amalfitano A et al. Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products. Hum Gene Ther 2001;12: 1741-1755. (Pubitemid 32911640)
28. Dudley RW, Lu Y, Gilbert R, Matecki S, Nalbantoglu J, Petrof BJ et al. Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther 2004;15: 145-156. (Pubitemid 38210530)
29. Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y et al. Type IV collageninitiated signals provide survival and growth cues required for liver metastasis. Oncogene 2011;30: 3766-3783.
30. Brunetti-Pierri N, Ng P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum Mol Genet 2011;20: R7-13.
31. Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulinlike growth factor receptor beta subunit. J Biol Chem 2001;276: 33608-33615.
32. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AKMG, Puntel M et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci 2010;107: 20021-20026.
33. Kim CY, Park SH, Jeong M, Kwon OS, Doh H, Kang SH et al. Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus-based gene therapy delivering secretable trimetic TRAIL. Exp Mol Med 2011;43: 580-586.
34. Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C et al. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther 2010;88: 204-213.
35. Auguste P, Fallavollita L, Wang N, Burnier J, Bikfalvi A, Brodt P. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 2007;170: 1781-1792. (Pubitemid 47339320)
36. Khatib AM, Auguste P, Fallavollita L, Wang N, Samani A, Kontogiannea M et al. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 2005;167: 749-759. (Pubitemid 41216359)
37. Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res 2002;62: 5393-5398.
38. Wu Y, Brodt P, Sun H, Mejia W, Novosyadlyy R, Nunez N et al. Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 2010;70: 57-67.
39. Kelley KW, Weigent DA, Kooijman R. Protein hormones and immunity. Brain Behav Immun 2007;21: 384-392. (Pubitemid 46553732)
40. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28: 3009-3021.
41. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27: 2516-2522.
42. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thoracic Oncol 2009;4: 1397-1403.
43. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001;98: 4605-4610. (Pubitemid 32295023)
44. Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ et al. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into nonhuman primates for liver-directed gene therapy. Mol Ther 2007;15: 732-740. (Pubitemid 46431993)